IRIS Accounts Production v24.3.2.46 SC685725 director 1.2.24 31.1.25 31.1.25 0 0 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWhSC6857252024-01-31SC6857252025-01-31SC6857252024-02-012025-01-31SC6857252023-01-31SC6857252023-02-012024-01-31SC6857252024-01-31SC685725ns15:Scotland2024-02-012025-01-31SC685725ns14:PoundSterling2024-02-012025-01-31SC685725ns10:Director12024-02-012025-01-31SC685725ns10:PrivateLimitedCompanyLtd2024-02-012025-01-31SC685725ns10:SmallEntities2024-02-012025-01-31SC685725ns10:AuditExempt-NoAccountantsReport2024-02-012025-01-31SC685725ns10:SmallCompaniesRegimeForDirectorsReport2024-02-012025-01-31SC685725ns10:SmallCompaniesRegimeForAccounts2024-02-012025-01-31SC685725ns10:FullAccounts2024-02-012025-01-31SC685725ns10:RegisteredOffice2024-02-012025-01-31SC685725ns5:CurrentFinancialInstruments2025-01-31SC685725ns5:CurrentFinancialInstruments2024-01-31SC685725ns5:ShareCapital2025-01-31SC685725ns5:ShareCapital2024-01-31SC685725ns5:RetainedEarningsAccumulatedLosses2025-01-31SC685725ns5:RetainedEarningsAccumulatedLosses2024-01-31SC685725ns5:ComputerEquipment2024-02-012025-01-31SC685725ns5:ComputerEquipment2025-01-31SC685725ns5:WithinOneYearns5:CurrentFinancialInstruments2025-01-31SC685725ns5:WithinOneYearns5:CurrentFinancialInstruments2024-01-31SC68572512024-02-012025-01-31
REGISTERED NUMBER: SC685725 (Scotland)



































Sanday Bioscience Limited

Financial Statements

for the Year Ended 31st January 2025






Sanday Bioscience Limited (Registered number: SC685725)






Contents of the Financial Statements
for the year ended 31st January 2025




Page

Company information 1

Balance sheet 2

Notes to the financial statements 3 to 5


Sanday Bioscience Limited

Company Information
for the year ended 31st January 2025







Director: Dr S M Matheson





Registered office: Academy House
Shedden Park Road
Kelso
Roxburghshire
TD5 7AL





Business address: Nether Monynut Cottage
Cockburnspath
Berwickshire
TD13 5YL





Registered number: SC685725 (Scotland)





Accountants: Rennie Welch LLP
Academy House
Shedden Park Road
Kelso
Roxburghshire
TD5 7AL

Sanday Bioscience Limited (Registered number: SC685725)

Balance Sheet
31st January 2025

2025 2024
Notes £    £    £    £   
Fixed assets
Tangible assets 4 1,666 -

Current assets
Debtors 5 19,065 -
Cash at bank 14,835 -
33,900 -
Creditors
Amounts falling due within one year 6 8,862 -
Net current assets 25,038 -
Total assets less current liabilities 26,704 -

Provisions for liabilities 317 -
Net assets 26,387 -

Capital and reserves
Called up share capital 50 -
Retained earnings 26,337 -
Shareholders' funds 26,387 -

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st January 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st January 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of income and retained earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 27th March 2025 and were signed by:




Dr S M Matheson - Director


Sanday Bioscience Limited (Registered number: SC685725)

Notes to the Financial Statements
for the year ended 31st January 2025

1. Statutory information

Sanday Bioscience Limited is a private company, limited by shares , registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.

2. Accounting policies

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover represents the total invoice value, excluding value added tax, of sales invoiced during the year, or the fair value of services provided for amounts not invoiced at the year end.

Turnover arising from the sale of goods is recognised when the significant risks and rewards of ownership have passed to the buyer. Turnover arising from the provision of services is recognised as contract activity progresses and the right to consideration is earned.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.
Office equipment - 25% on cost

Tangible fixed assets are stated at cost less accumulated depreciation and accumulated impairment losses.

Financial instruments
The following assets and liabilities are classified as financial instruments - trade debtors, accruals and directors' loans.

Directors' loans (being repayable on demand), trade debtors and accruals are measured at the undiscounted amount of the cash or other consideration expected to be paid or received.

Financial assets that are measured at amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of Income and Retained Earnings.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Sanday Bioscience Limited (Registered number: SC685725)

Notes to the Financial Statements - continued
for the year ended 31st January 2025

2. Accounting policies - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Provisions
Provisions are set up only where it is probable that a present obligation exists as a result of an event prior to the balance sheet date and that a payment will be required in settlement that can be estimated reliably. Where material, provisions are calculated on a discounted basis.

Going concern
The director has considered the company's financial position for a minimum period of 12 months and beyond from the date of signing these financial statements and have an expectation that the company should be in a position to continue trading in the current format for the foreseeable future. Accordingly, she continues to adopt the going concern basis in preparing these financial statements

3. Employees and directors

The average number of employees during the year was NIL (2024 - NIL).

4. Tangible fixed assets
Office
equipment
£   
Cost
Additions 1,999
At 31st January 2025 1,999
Depreciation
Charge for year 333
At 31st January 2025 333
Net book value
At 31st January 2025 1,666

5. Debtors: amounts falling due within one year
2025 2024
£    £   
Trade debtors 6,241 -
Other debtors 12,824 -
19,065 -

Sanday Bioscience Limited (Registered number: SC685725)

Notes to the Financial Statements - continued
for the year ended 31st January 2025

6. Creditors: amounts falling due within one year
2025 2024
£    £   
Taxation and social security 5,862 -
Other creditors 3,000 -
8,862 -

7. Director's advances, credits and guarantees

Included within other debtors are the following loans to the director:

at 31 JanAmountAmountat 31 Jan
2024AdvancedRepaid2025

Director-14,144(1,320)12,824

This loan is unsecured, repayable on demand and interest has been charged at the official rates published by HMRC.

8. Post balance sheet events

On 26th March 2025 an interim dividend of £400 per share was declared.